Orphan Drug Designation Granted for New IPF Treatment

Good news for Prometic Life Science new drug application! The pharmaceutical company has been searching for a cure for idiopathic pulmonary fibrosis (IPF), a rare lung disease which you can learn more about here.

The application for their new drug Ryplazim (plasminogen) has received Orphan Drug Designation from the U.S. FDA. Orphan Drug Designation helps pharmaceutical companies develop treatments for rare diseases by offering tax credits and other benefits.

Read the full article at Pulmonary Fibrosis News.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email